Clinical Trials Logo

Clinical Trial Summary

We recently described the ROX index, defined as the ratio of SpO2/FIO2 to respiratory rate that outperformed the diagnostic accuracy of the two variables separately. Patients who had a ROX index ≥4.88 after 12 hours of HFNC therapy were less likely to be intubated, even after adjusting for potential covariates. Like any other scoring system, an independent validation of the score in a different population is necessary. We therefore undertook a multicenter, prospective study to validate the ROX index's diagnostic accuracy for determining which patients will fail on HFNC and will need to be intubated.


Clinical Trial Description

A growing interest in the non-invasive management of acute respiratory failure has been fuelled by the advent of high-flow nasal canula oxygen therapy (HFNC) and recent data showing that use of HFNC was associated with lower mortality, more ventilator-free days and lower risk for intubation in subsets of patients with PaO2/FIO2≤200mmHg or in those who were immunocompromised in comparison with non-invasive ventilation or standard oxygen. These positive results in favour of HFNC followed physiological studies indicating oxygenation and comfort improvements associated with HFNC use. This has led clinicians to try this technique in the most severe respiratory failure patients, those with ARDS.

Consubstantial to the increasing use of HFNC is the risk of delaying intubation. This is a major concern since a large body of evidence has shown that patients that fail non-invasive ventilatory management of de novo acute respiratory failure (ARF) have a worse outcome.

The variability in both the decision to intubate and its timing reported in several studies suggest that clinical parameters such as respiratory parameters alone are not sufficient and that the progression of the respiratory failure is not sufficiently taken into account. To address this need, we investigated a new score to identify patients at risk of intubation to help clinicians, with three goals simple to use, accurate, and immediately performable at the patients' bedside by any staff. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02845128
Study type Observational
Source Hospital Universitari Vall d'Hebron Research Institute
Contact
Status Completed
Phase
Start date May 2016
Completion date September 2017

See also
  Status Clinical Trial Phase
Terminated NCT02377609 - To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks N/A
Completed NCT05236101 - Validation of Child Drawing Hospital Scale (CD: H) and the Place of the Drawing in the Evaluation of Dental Anxiety N/A
Completed NCT04778007 - The Validation of the Turkish Version of the LUMP Questionnaire
Recruiting NCT05871411 - Validation of Visual Analog Scales to Measure SatisfactiOn and WELL-being at Work (SoWell-VAS)
Completed NCT03162835 - Development and Clinimetric Properties of the Dutch Pediatric Neurophysiology of Pain Questionnaire in Healthy Children
Not yet recruiting NCT06392698 - The Danish Version of the Surgical Fear Questionnaire
Recruiting NCT05970835 - Validation of a Mobile App as an Adjuvant Treatment N/A
Completed NCT04465903 - Validity and Reliability of the Turkish Version of the Sydney Swallow Questionnaire
Completed NCT04477174 - Validity and Reliability of the Turkish Translation of the Yale Pharyngeal Residue Severity Rating Scale
Completed NCT02625285 - Validation of New G6PD Point of Care Tests Against Gold Standard Quantitative N/A
Not yet recruiting NCT04208672 - Validation of a Handy Sleep Monitoring Device: UMindSleep in Patients With Obstructive Sleep Apnea N/A
Completed NCT00340756 - Evaluating Serum Sex Steroid Hormones N/A
Completed NCT05678920 - Validation of the Turkish Version of the Modified Early Obstetric Warning Systems (MEOWS) Charts